Antibody Discovery

Chapter Outlines

Chapter 2 provides an executive summary of the insights captured in our research. It presents a high-level view on the current scenario within the antibody discovery services and platform market and its evolution in the short-mid-term and long term.

Chapter 3 provides a general introduction of antibodies featuring details on their historical background, structure, isotypes, mechanism of action and applications. It also emphasizes on the different types of antibodies, namely monoclonal, bispecific and polyclonal antibodies.

Chapter 4 features a detailed overview on the antibody discovery process and the various methods used in the discovery of these therapeutic biomolecules. It also highlights a comparison of different antibody discovery methods that are currently available. Additionally, the chapter provides insights on the gradual shift in development trends of monoclonal antibodies over the last three decades, tracking the transition from fully murine to fully human product variants.

Chapter 5 provides a general overview of the current market landscape of more than 80 service providers that are currently active in this domain. It features a detailed analysis of these players based on several parameters, such as year of establishment, company size, location of headquarters, type of service offered (antigen designing, hit generation, lead selection, and lead optimization and lead characterization), type of antibody discovery method (hybridoma based, library based, single cell based, transgenic animal based, and others), animal model used (rabbit, rat, mouse, llama, chicken, transgenic animal and others), type of antibody discovered (monoclonal antibody, bispecific antibody, single domain antibody, antibody drug conjugate, antibody fragment and others) and purpose of antibody discovery (therapeutic and diagnostic).

Chapter 6 provides an insightful competitiveness analysis of antibody discovery service providers that we came across during our research. The analysis compares the companies on the basis of supplier strength (based on the year of establishment of the service provider) and service strength (which takes into account the number of antibody discovery services offered, number of antibody discovery methods adopted, and number of subject specific agreements signed).

Chapter 7 provides detailed profiles of the stakeholders that are actively engaged in providing antibody discovery services to biopharmaceutical companies. Each company profile includes a brief overview of the company, its financial information (if available), details on antibody discovery services, recent developments and an informed future outlook.

Chapter 8 presents the current market landscape of over 120+ antibody discovery platform providers, including information on their company details such as year of establishment, company size, location of headquarters and type of antibody discovered (monoclonal antibody, bispecific antibody, single domain antibody, antibody drug conjugate, antibody fragment and others). In addition, the chapter highlights an in-depth analysis of 170+ antibody discovery platforms based on type of antibody discovery method (hybridoma based, library-based, single cell-based, transgenic animal-based, and others), animal model used (rabbit, rat, mouse, llama, chicken, transgenic animal and others) and availability of intellectual property.

Chapter 9 provides an insightful competitiveness analysis of antibody discovery platforms. It highlights the leading players in this domain, taking into consideration the supplier power (based on the year of establishment of the platform provider) and key specifications of the platforms, such as type of antibody discovered, compatibility of antibodies in human (fully human or not), availability of patent protection, number of deals signed for a particular platform (2015-2021).  

Chapter 10 provides detailed profiles of the stakeholders, which actively provide access / licenses to their antibody discovery technology / platforms to other companies. Each company profile includes a brief overview of the company, its financial information (if available), details on antibody discovery technology / platforms, recent developments and an informed future outlook

Chapter 11 presents the antibody discovery capabilities in different regions, based on a number of relevant parameters, such as type of service offered for service providers, and number of technologies offered, number of antibody discovery methods and type of antibody discovered for platform providers.

Chapter 12 features an in-depth analysis and discussion on the various partnerships that have been inked between the players in this market in the time period between 2015 and 2021 (till November). It includes a brief description of partnership models (such as acquisitions, product development agreements, product integration agreements, commercialization agreements, clinical trial agreements, licensing agreements, manufacturing agreements, and service agreements) adopted by the stakeholders.

Chapter 13 presents an analysis of the investments made in this domain during the period 2016-2021 (till November), including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings, at various stages of discovery in companies that are focused on antibody discovery.

Chapter 14 features an insightful market forecast analysis, highlighting the likely growth of antibody discovery services domain till the year 2035. In order to provide details on the future opportunities, our projections have been segmented on the basis of  [A] the various steps involved in antibody discovery (antigen designing, hit generation, lead selection, lead optimization and lead characterization), [B] antibody discovery method (hybridoma based, library-based, single cell-based, transgenic animal-based, animal-based and others), [C] the nature of antibody generated (whether human/ fully human or not) and [D] key geographical regions (North America, Europe and Asia- Pacific and rest of the world). 

Chapter 15 presents the likely growth of antibody discovery platform market, on the basis of licensing deal structures and agreements signed or planned in the foreseen future. In order to provide details on the future opportunities, the projections have been segmented on the basis of 
key geographical regions (North America, Europe and Asia- Pacific).

Chapter 16 provides deal structure analysis, highlighting cash flows and net present values of licensor and licensee, taking into consideration multiple likely scenarios of upfront, milestone and royalty payments.

Chapter 17 features detailed profiles of the most successful therapeutic monoclonal antibody products (as per sales reported in 2020). It provides information on top five drugs, namely Humira®, Keytruda®, Stelara®, Opdivo® and Avastin®, their historical sales, and discovery process and methods.
    
Chapter 18 features a case study on antibody humanization and affinity maturation, highlighting the importance of these methods in the process of antibody discovery and development. The chapter presents a list of key players along with the information on their respective location, their expertise across antibody humanization and / or affinity maturation, the methodology adopted for providing such services and the revenue / business models adopted by the players involved in this domain. In addition, chapter provides insights on a publication analysis representing the recent trends in research on antibody humanization across various academic institutes, highlighting the ongoing innovation in this domain. Further, the report features a detailed SWOT analysis, which elaborates on the various drivers and challenges that are likely to influence the activities of players engaged in this domain.

Chapter 19 provides an overview of future growth opportunities in the field of antibody discovery. The chapter discusses the upcoming antibody therapeutics and technologies, which are being developed / adopted by the antibody drug discovery service and platform providers that are likely to have influence on the industry’s evolution over the coming decade.

Chapter 20 is a collection of interview transcripts of the discussions held with key stakeholders in this market. In this chapter, we have presented the details of our conversations with (in alphabetical order of person name) Tracey Mullen (Chief Executive Officer, Abveris Antibody), Lisa Delouise (Founder and Chief Technology Officer, Nidus Biosciences), Mark Kubik (Chief Business Officer, AvantGen), Chun-Nan Chen (Chief Executive Officer and Chief Scientific Officer, Single Cell Technology), Giles Day (Co-Founder and Chief Executive Officer, Distributed Bio), Kevin Heyries (Co-Founder and Lead of Business Development Strategy, AbCellera), Sanjiban K Banerjee (Director, AbGenics Life Sciences), Ignacio Pino (Chief Executive Officer and President, CDI Laboratories), Jeng Her (Chief Executive Officer, AP Biosciences), Thomas Schirrmann (Chief Executive Officer and General Manager, YUMAB), Debra Valsamis (Business Development Associate, Antibody Solutions),  Christel Iffland (Vice President, Ligand Pharmaceuticals), Aaron Sato (Chief Scientific Officer, LakePharma / Twist Biosciences)

Chapter 21 summarizes the entire report, highlighting the various facts related to contemporary market trend and the likely evolution of the antibody discovery service and platform market.

Chapter 22 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 23 is an appendix, which contains the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION 
3.1. Chapter Overview
3.2. Structure of Antibodies
3.3. History of Antibody Development
3.4. Antibody Isotypes
3.5. Mechanism of Action of Antibodies 
3.6. Classification of Antibodies
3.6.1. Monoclonal Antibodies
3.6.2. Polyclonal Antibodies
3.6.3. Bispecific Antibodies
3.7. Applications of Antibodies
3.8. Concluding Remarks

4. ANTIBODY DISCOVERY PROCESS AND METHODS
4.1. Chapter Overview
4.2. Antibody Discovery Process
4.2.1. Target Selection and Validation
4.2.2. Hit Generation
4.2.3. Lead Selection
4.2.4. Lead Optimization
4.2.4.1. Humanization
4.2.4.2. Affinity Maturation
4.2.4.3. Fc Engineering
4.2.5. Lead Characterization
4.2.6. Candidate Selection

4.3. Antibody Discovery Methods
4.3.1. Hybridoma Technology-Based Method
4.3.2. In vitro Display Method
4.3.2.1. Phage Display
4.3.2.2. Yeast Display
4.3.2.3. Ribosomal Display
4.3.3. Transgenic Animal-Based Method
4.3.4. Single B Cell-Based Method
4.3.5. Advantages and Disadvantages of Existing Antibody Discovery Techniques

4.4. Evolution of Monoclonal Antibodies
4.4.1. Fully Human Monoclonal Antibodies

5. ANTIBODY DISCOVERY SERVICE PROVIDERS: CURRENT MARKET LANDSCAPE
5.1. Chapter Overview
5.2. Antibody Discovery Service Providers: List of Industry Players
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Location of Headquarters
5.2.4. Analysis by Type of Service Offered
5.2.5. Analysis by Company Size and Type of Service Offered
5.2.6. Analysis by Type of Antibody Discovery Method
5.2.7. Grid Representation: Analysis by Type of Antibody Discovery Method, Type of Antibody Discovered and Location of Headquarters
5.2.8. Analysis by Animal Model Used
5.2.9. Analysis by Type of Antibody Discovered
5.2.10. Analysis by Type of Antibody Discovery Method and Type of Antibody Discovered
5.2.11. Analysis by Purpose of Antibody Discovery

6. COMPANY COMPETITIVENESS ANALYSIS
6.1. Chapter Overview
6.2. Methodology
6.3. Key Parameters
6.4. Competitiveness Analysis: Antibody Discovery Service Providers
6.4.1. Antibody Discovery Service Providers based in North America
6.4.2. Antibody Discovery Service Providers based in Europe
6.4.3. Antibody Discovery Service Providers based in Asia-Pacific

7. COMPANY PROFILES: ANTIBODY DISCOVERY SERVICE PROVIDERS
7.1. Chapter Overview
7.2. Antibody Discovery Service Providers in North America
7.2.1. Abwiz Bio
7.2.1.1. Company Overview
7.2.1.2. Antibody Discovery Services Portfolio
7.2.1.3. Recent Developments and Future Outlook

7.2.2. Aragen Bioscience (a GVK BIO company)
7.2.2.1. Company Overview
7.2.2.2. Antibody Discovery Services Portfolio
7.2.2.3. Recent Developments and Future Outlook

7.2.3. Creative Biolabs
7.2.3.1. Company Overview
7.2.3.2. Antibody Discovery Services Portfolio
7.2.3.3. Recent Developments and Future Outlook

7.2.4. Distributed Bio
7.2.4.1. Company Overview
7.2.4.2. Antibody Discovery Services Portfolio
7.2.4.3. Recent Developments and Future Outlook

7.2.5. ImmunoPrecise Antibodies
7.2.5.1. Company Overview
7.2.5.2. Financial Information
7.2.5.3. Antibody Discovery Services Portfolio
7.2.5.4. Recent Developments and Future Outlook

7.2.6. Integral Molecular
7.2.6.1. Company Overview
7.2.6.2. Antibody Discovery Services Portfolio
7.2.6.3. Recent Developments and Future Outlook

7.2.7. LakePharma
7.2.7.1. Company Overview
7.2.7.2. Antibody Discovery Services Portfolio
7.2.7.3. Recent Developments and Future Outlook

7.2.8. Syd Labs
7.2.8.1. Company Overview
7.2.8.2. Antibody Discovery Services Portfolio

7.3. Antibody Discovery Service Providers in Europe
7.3.1. Abzena
7.3.1.1. Company Overview
7.3.1.2. Financial Information
7.3.1.3. Antibody Discovery Services Portfolio
7.3.1.4. Recent Developments and Future Outlook

7.3.2. BIOTEM
7.3.2.1. Company Overview
7.3.2.2. Antibody Discovery Services Portfolio
7.3.2.3. Recent Developments and Future Outlook

7.3.3. PX'Therapeutics (Subsidiary of Aguettant Pharmaceutical Group)
7.3.3.1. Company Overview
7.3.3.2. Antibody Discovery Services Portfolio
7.3.3.3. Recent Developments and Future Outlook

7.4. Antibody Discovery Service Providers in Asia-Pacific
7.4.1. ChemPartner
7.4.1.1. Company Overview
7.4.1.2. Antibody Discovery Services Portfolio
7.4.1.3. Recent Developments and Future Outlook

7.4.2. HD Biosciences
7.4.2.1. Company Overview
7.4.2.2. Antibody Discovery Services Portfolio

7.4.3. Viva Biotech
7.4.3.1. Company Overview
7.4.3.2. Financial Information
7.4.3.3. Antibody Discovery Services Portfolio
7.4.3.4. Recent Developments and Future Outlook

7.4.4. WuXi Biologics
7.4.4.1. Company Overview
7.4.4.2. Financial Information
7.4.4.3. Antibody Discovery Services Portfolio
7.4.4.4. Recent Developments and Future Outlook

8. ANTIBODY DISCOVERY TECHNOLOGIES: CURRENT MARKET LANDSCAPE
8.1. Chapter Overview
8.2. Antibody Discovery Platform Providers: List of Industry Players
8.2.1. Analysis by Year of Establishment
8.2.2. Analysis by Company Size 
8.2.3. Analysis by Location of Headquarters
8.2.4. Analysis by Type of Antibody Discovered
8.3. Antibody Discovery: List of Technologies and Platforms
8.3.1. Analysis by Type of Antibody Discovery Method
8.3.2. Analysis by Type of Antibody Discovery Method and Location of Headquarters
8.3.3. Analysis by Animal Model Used
8.3.4. Analysis by Patent Availability

9. TECHNOLOGY COMPETITIVENESS ANALYSIS
9.1. Chapter Overview
9.2. Methodology
9.3. Library based Antibody Discovery Platforms
9.3.1. Key Assumptions and Parameters
9.3.2. Technology Competitiveness Analysis
9.4. Single Cell based Antibody Discovery Platforms 
9.4.1 Key Assumptions and Parameters

9.4.2. Technology Competitiveness Analysis 
9.5. Transgenic Animal based Antibody Discovery Platforms
9.5.1. Key Assumptions and Parameters
9.5.2. Technology Competitiveness Analysis
9.6. Hybridoma based Antibody Discovery Platforms
9.6.1. Key Assumptions and Parameters
9.6.2. Technology Competitiveness Analysis
9.7. Other Antibody Discovery Platforms 
9.7.1. Key Assumptions and Parameters
9.7.2. Technology Competitiveness Analysis 

10. COMPANY PROFILES: ANTIBODY DISCOVERY PLATFORM PROVIDERS
10.1. Chapter Overview
10.2. Harbour BioMed
10.2.1. Company Overview
10.2.2.  Antibody Discovery Platforms Portfolio
10.2.2.1. H2L2 Platform
10.2.2.2. HCAb Platform
10.2.3. Recent Developments and Future Outlook 

10.3. ImmunoPrecise Antibodies
10.3.1. Company Overview
10.3.2. Financial Information
10.3.3. Antibody Discovery Platforms Portfolio 
10.3.3.1. Abthena™
10.3.3.2. B cell Select™
10.3.3.3. DeepDisplay™
10.3.3.4. ModiFuse™
10.3.3.5. ModiPhage™
10.3.3.6. ModiSelect™
10.3.3.7. ModiTune™
10.3.4. Recent Developments and Future Outlook

10.4. Kymab
10.4.1. Company Overview
10.4.2. Antibody Discovery Platforms Portfolio 
10.4.2.1. Kymouse™
10.4.2.2. IntelliSelect®
10.4.3. Recent Developments and Future Outlook

10.5. Ligand Pharmaceuticals
10.5.1. Company Overview
10.5.2. Financial Information
10.5.3. Antibody Discovery Platforms Portfolio 
10.5.3.1. OmniAb®
10.5.3.1.1. OmniChicken®
10.5.3.1.2. OmniClic™
10.5.3.1.3. OmniFlic®
10.5.3.1.4. OmniMouse®
10.5.3.1.5. OmniRat®
10.5.4. Recent Developments and Future Outlook

10.6. MorphoSys
10.6.1. Company Overview
10.6.2. Financial Information
10.6.3. Antibody Discovery Platforms Portfolio 
10.6.3.1. arYla® Technology
10.6.3.2. HuCAL® Technology
10.6.3.3. Ylanthia® Technology
10.6.4. Recent Developments and Future Outlook

11. REGIONAL CAPABILITY ANALYSIS
11.1. Chapter Overview
11.2. Key Assumptions and Methodology
11.3. Regional Capability Analysis: Antibody Discovery Service Providers
11.3.1 Regional Capability Analysis: Antibody Discovery Service Providers in North America
11.3.2. Regional Capability Analysis: Antibody Discovery Service Providers in Europe
11.3.3. Regional Capability Analysis: Antibody Discovery Service Providers in Asia-Pacific
 
11.4. Regional Capability Analysis: Antibody Discovery Platform Providers
11.4.1. Regional Capability Analysis: Distribution of Antibody Discovery Platform Providers in North America
11.4.2. Regional Capability Analysis: Distribution of Antibody Discovery Platform Providers in Europe
11.4.3. Regional Capability Analysis: Distribution of Antibody Discovery Platform Providers in Asia-Pacific

11.5. Concluding Remarks

12. PARTNERSHIPS AND COLLABORATIONS
12.1. Chapter Overview
12.2. Partnership Models
12.3. List of Partnerships and Collaborations
12.3.1. Analysis by Year of Partnership
12.3.2. Analysis by Type of Partnership
12.3.3. Analysis by Type of Company (Service / Platform Providers)
12.3.4. Analysis by Type of Antibody Discovered
12.3.5. Analysis by Year of Partnership and Type of Partner
12.3.6. Analysis by Type of Partnership and Type of Partner
12.3.7. Most Active Players: Analysis by Number of Partnerships
12.3.8. Most Popular Technologies: Analysis by Number of Partnerships
12.3.9. Regional Analysis
12.3.9.1. Intercontinental and Intracontinental Agreements

13. FUNDING AND INVESTMENT ANALYSIS
13.1. Chapter Overview
13.2. Types of Funding
13.3. Antibody Discovery Service and Platform Providers: Funding and Investment Analysis
13.3.1. Analysis by Number of Funding Instances
13.3.2. Analysis by Amount Invested
13.3.3. Analysis by Type of Funding
13.3.4. Most Active Players: Analysis by Amount Invested
13.3.5. Most Active Investors: Analysis by Number of Funding Instances
13.3.6. Regional Analysis by Amount Invested

13.4. Concluding Remarks

14. ANTIBODY DISCOVERY SERVICES: MARKET FORECAST
14.1. Chapter Overview
14.2. Forecast Methodology
14.3. Global Antibody Discovery Services Market, 2021-2035
14.4. Global Antibody Discovery Services Market: Distribution by Steps Involved in Antibody Discovery Process, 2021-2035
14.4.1. Antibody Discovery Services Market for Antigen Designing, 2021-2035
14.4.2. Antibody Discovery Services Market for Hit Generation, 2021-2035
14.4.3. Antibody Discovery Services Market for Lead Selection, 2021-2035
14.4.4. Antibody Discovery Services Market for Lead Optimization, 2021-2035
14.4.5. Antibody Discovery Services Market for Lead Characterization, 2021-2035

14.5. Global Antibody Discovery Services Market: Distribution by Antibody Discovery Method, 2021-2035
14.5.1. Antibody Discovery Services Market for Phage Display, 2021-2035
14.5.2. Antibody Discovery Services Market for Yeast Display, 2021-2035
14.5.3. Antibody Discovery Services Market for Hybridoma Method, 2021-2035
14.5.4. Antibody Discovery Services Market for Transgenic Animal Based Method, 2021-2035
14.5.5. Antibody Discovery Services Market for Single Cell Based Method, 2021-2035
14.5.6. Antibody Discovery Services Market for Other Methods, 2021-2035

14.6. Global Antibody Discovery Services Market: Distribution by Nature of Antibody Generated, 2021-2035
14.6.1. Antibody Discovery Services Market for Humanized Antibodies, 2021-2035
14.6.2. Antibody Discovery Services Market for Human Antibodies, 2021-2035
14.6.3. Antibody Discovery Services Market for Chimeric Antibodies, 2021-2035
14.6.4. Antibody Discovery Services Market for Murine Antibodies, 2021-2035

14.7. Global Antibody Discovery Services Market: Distribution by Region, 2021-2035
14.7.1. Antibody Discovery Services Market in North America, 2021-2035
14.7.2. Antibody Discovery Services Market in Europe, 2021-2035
14.7.3. Antibody Discovery Services Market in Asia-Pacific and Rest of the World, 2021-2035
14.7.4. Antibody Discovery Services: Market Attractiveness Analysis by Region

15. ANTIBODY DISCOVERY TECHNOLOGIES: MARKET FORECAST
15.1. Chapter Overview
15.2. Key Assumptions
15.3. Forecast Methodology
15.4. Global Antibody Discovery Platforms Market, 2021-2035
15.5. Global Antibody Discovery Platforms Market: Distribution by Region, 2021-2035
15.5.1. Antibody Discovery Platforms Market in North America, 2021-2035
15.5.2. Antibody Discovery Platforms Market in Europe, 2021-2035
15.5.3. Antibody Discovery Platforms Market in Asia-Pacific, 2021-2035

16. LICENSING DEAL STRUCTURE

17. CASE IN POINT: DRUG DISCOVERY PROCESSES OF TOP SELLING ANTIBODIES
17.1. Chapter Overview
17.2. Humira® (Adalimumab)
17.2.1. Drug Overview
17.2.2. Discovery Process and Method
17.2.3. Historical Sales

17.3. Keytruda® (Pembrolizumab)
17.3.1. Drug Overview
17.3.2. Discovery Process and Method
17.3.3. Historical Sales

17.4. Stelara® (Ustekinumab)
17.4.1. Drug Overview
17.4.2. Discovery Process and Method
17.4.3. Historical Sales

17.5. Opdivo® (Nivolumab)
17.5.1. Drug Overview
17.5.2. Discovery Process and Method
17.5.3. Historical Sales

17.6. Avastin® (Bevacizumab)
17.6.1. Drug Overview
17.6.2. Discovery Process and Method
17.6.3. Historical Sales

18. CASE STUDY: ANTIBODY HUMANIZATION AND AFFINITY MATURATION
18.1. Importance of Antibody Humanization and Affinity Maturation
18.2. Antibody Humanization and Affinity Maturation Service and Platform Providers: Market Landscape
18.3. Antibody Humanization: Publication Analysis
18.3.1. Publication Analysis: Year-Wise Trend
18.3.2. Publication Analysis: Key Journals
18.3.3. Publication Analysis: Distribution by Animal Model Used
18.3.4. Publication Analysis: Distribution by Antibody Humanization Method
18.4. Antibody Humanization Service and Platform Providers: SWOT Analysis

19. FUTURE GROWTH OPPORTUNITIES IN ANTIBODY DISCOVERY
19.1. Chapter Overview
19.2. Anticipated Shift from Monoclonal Antibodies to Other Novel Antibody Formats
19.3. Technological Advancements to Overhaul Conventional Antibody Discovery Processes
19.4. Transition to CADD-based Approaches to Help Achieve Better Operational Efficiencies
19.5. Rising Demand for Antibody-based Treatment Options for Non-Oncological Indications
19.6. Future Growth Opportunities in the Asia-Pacific Region
19.7. Expected Increase in Number of Collaborations and Licensing Activity
19.8 Concluding Remarks

20. CONCLUDING REMARKS
20.1. Chapter Overview

21. EXECUTIVE INSIGHTS
21.1. Chapter Overview

21.2. Abveris Antibody
21.2.1. Company Snapshot
21.2.2. Tracey Mullen, Chief Executive Officer (Q2 2020)

21.3. Nidus Biosciences
21.3.1. Company Snapshot
21.3.2. Lisa Delouise, Founder and Chief Technology Officer (Q1 2020)

21.4. AvantGen
21.4.1. Company Snapshot
21.4.2. Mark Kubik, Chief Business Officer(Q1 2020)

21.5. Single Cell Technology
21.5.1. Company Snapshot
21.5.2. Chun-Nan Chen, Chief Executive Officer and Chief Scientific Officer (Q2 2018)

21.6. Distributed Bio
21.6.1. Company Snapshot
21.6.2. Giles Day, Co-Founder and Chief Executive Officer (Q2 2018)

21.7. AbCellera
21.7.1. Company Snapshot
21.7.2. Kevin Heyries, Co-Founder and Lead of Business Development Strategy (Q2 2018)

21.8. AbGenics Life Sciences
21.8.1. Company Snapshot
21.8.2. Sanjiban K Banerjee, Director (Q2 2018)

21.9. CDI Laboratories
21.9.1. Company Snapshot
21.9.2. Ignacio Pino, Chief Executive Officer and President (Q2 2017)

21.10. AP Biosciences
21.10.1. Company Snapshot
19.10.2. Jeng Her, Chief Executive Officer (Q2 2017)

21.11. YUMAB
21.11.1. Company Snapshot
21.11.2. Thomas Schirrmann, Chief Executive Officer and General Manager (Q2 2017)

21.12. Antibody Solutions
21.12.1. Company Snapshot
21.12.2. Debra Valsamis, Business Development Associate (Q2 2017)

21.13. Ligand Pharmaceuticals
21.13.1. Company Snapshot
21.13.2. Christel Iffland, Vice President (Q2 2017)

21.14. LakePharma
21.14.1. Company Snapshot
21.14.2. Aaron Sato, Chief Scientific Officer (Q2 2017)

22. APPENDIX 1: TABULATED DATA

23. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATION

List Of Figures

Figure 3.1 Basic Structure of an Antibody
Figure 3.2 Historical Timeline of Antibody Development
Figure 3.3 Mechanism of Action of Antibodies
Figure 3.4 Applications of Antibodies
Figure 4.1 Overview of the Antibody Discovery Process
Figure 4.2 Antibody Discovery Process: Hybridoma Method
Figure 4.3 Antibody Discovery Process: Phage Display Method
Figure 4.4 Antibody Generation Using Transgenic Animals
Figure 4.5 Approved Monoclonal Antibodies: Development Trend Analysis
Figure 4.6 Approval Timeline of Fully Human Monoclonal Antibodies
Figure 4.7 Discovery Methods of Fully Human Monoclonal Antibodies
Figure 5.1 Antibody Discovery Service Providers: Distribution by Year of Establishment
Figure 5.2 Antibody Discovery Service Providers: Distribution by Company Size
Figure 5.3 Antibody Discovery Service Providers: Distribution by Location of Headquarters
Figure 5.4 World Map Representation: Distribution by Location by Headquarters
Figure 5.5 Antibody Discovery Service Providers: Distribution by Type of Service Offered
Figure 5.6 Antibody Discovery Service Providers: Distribution by Company Size and Type of Service Offered
Figure 5.7 Antibody Discovery Service Providers: Distribution by Type of Antibody Discovery Method
Figure 5.8 Grid Representation: Distribution by Type of Antibody Discovery Method, Type of Antibody Discovered and Location of Headquarters
Figure 5.9 Antibody Discovery Service Providers: Distribution by Animal Model Used
Figure 5.10 Antibody Discovery Service Providers: Distribution by Type of Antibody Discovered
Figure 5.11 Antibody Discovery Service Providers: Distribution by Type of Antibody Discovery Method and Type of Antibody Discovered
Figure 5.12 Antibody Discovery Service Providers: Distribution by Purpose of Antibody Discovery
Figure 6.1 Competitiveness Analysis: Antibody Discovery Service Providers based in North America
Figure 6.2 Competitiveness Analysis: Antibody Discovery Service Providers based in Europe
Figure 6.3 Competitiveness Analysis: Antibody Discovery Service Providers based in Asia-Pacific
Figure 7.1 Abzena: Annual Revenues, 2014-2018 (GBP Million)
Figure 7.2 ImmunoPrecise Antibodies: Annual Revenues, 2016-2021 (USD Million)
Figure 7.3 Viva Biotech: Annual Revenues, 2016-H1 2021 (RMB Million)
Figure 7.4 WuXi Biologics: Annual Revenues, 2015-H1 2021 (RMB Billion)
Figure 8.1 Antibody Discovery Platform Providers: Distribution by Year of Establishment
Figure 8.2 Antibody Discovery Platform Providers: Distribution by Company Size
Figure 8.3 Antibody Discovery Platform Providers: Distribution by Location of Headquarters
Figure 8.4 World Map Representation: Distribution by Location by Headquarters
Figure 8.5 Antibody Discovery Platform Providers: Distribution by Type of Antibody Discovered
Figure 8.6 Antibody Discovery Platforms: Distribution by Type of Antibody Discovery Method
Figure 8.7 Antibody Discovery Platforms: Distribution by Type of Antibody Discovery Method and Location of Headquarters
Figure 8.8 Antibody Discovery Platforms: Distribution by Animal Model Used
Figure 8.9 Antibody Discovery Platforms: Distribution by Patent Availability
Figure 9.1 Competitiveness Analysis: Library based Antibody Discovery Platforms
Figure 9.2 Competitiveness Analysis: Single Cell based Antibody Discovery Platforms
Figure 9.3 Competitiveness Analysis: Transgenic Animal based Antibody Discovery Platforms
Figure 9.4 Competitiveness Analysis: Hybridoma based Antibody Discovery Platforms
Figure 9.5 Competitiveness Analysis: Other Antibody Discovery Platforms
Figure 10.1 ImmunoPrecise Antibodies: Annual Revenues, 2016-2021 (USD Million)
Figure 10.2 Ligand Pharmaceuticals: Annual Revenues, 2014-9M 2021 (USD Million)
Figure 10.3 MorphoSys: Annual Revenues, 2014-9M 2021 (USD Million)
Figure 11.1 Regional Capability Analysis: Antibody Discovery Service Providers based in North America
Figure 11.2 Regional Capability Analysis: One-Stop Shops in North America
Figure 11.3 Regional Capability Analysis: Antibody Discovery Service Providers based in Europe
Figure 11.4 Regional Capability Analysis: One-Stop Shops in Europe
Figure 11.5 Regional Capability Analysis: Antibody Discovery Service Providers based in Asia-Pacific
Figure 11.6 Regional Capability Analysis: One-Stop Shops in Asia-Pacfic
Figure 11.7 Regional Capability Analysis: Concluding Remarks
Figure 12.1 Partnerships and Collaborations: Cumulative Trend by Year, 2015-2021
Figure 12.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 12.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership, 2015-2020
Figure 12.4 Partnerships and Collaborations: Distribution by Type of Company (Service / Platform Providers)
Figure 12.5 Partnerships and Collaborations: Distribution by Type of Antibody Discovered
Figure 12.6 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Figure 12.7 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Figure 12.8 Most Active Players: Distribution by Number of Partnerships
Figure 12.9 Most Popular Technologies: Distribution by Number of Partnerships
Figure 12.10 Partnerships and Collaborations: Regional Distribution
Figure 12.11 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
Figure 13.1 Funding and Investment Analysis: Distribution by Type of Funding and Year of Establishment
Figure 13.2 Funding and Investment Analysis: Cumulative Year-wise Distribution of Funding Instances, 2016-2021
Figure 13.3 Funding and Investment Analysis: Year-wise Distribution of Funding Instances by Type of Company, (2016-2021)
Figure 13.4 Funding and Investment Analysis: Distribution by Cumulative Amount Invested, 2016-2021 (USD Million)
Figure 13.5 Funding and Investment Analysis: Year-wise Distribution of Funding Instances by Amount Invested, 2016-2021 (USD Million)
Figure 13.6 Funding and Investment Analysis: Year-wise Distribution of the Amount Raised by Type of Company, 2016-2021 (USD Million)
Figure 13.7 Funding and Investment Analysis: Distribution of Instances by Type of Funding,
Figure 13.8 Funding and Investment Analysis: Distribution of Type of Funding and Amount Invested, (USD Million)
Figure 13.9 Most Active Player: Distribution by Number of Funding Instances
Figure 13.10 Most Active Player: Distribution by Total Amount Invested (USD Million)
Figure 13.11 Most Active Investors: Distribution by Number of Funding Instances
Figure 13.12 Funding and Investment Analysis: Distribution by Geography
Figure 13.13 Funding and Investment Analysis: Regional Distribution of Funding Instances
Figure 13.14 Funding and Investment Summary
Figure 14.1 Global Antibody Discovery Services Market, 2021-2035 (USD Billion)
Figure 14.2 Global Antibody Discovery Services Market: Distribution by Steps Involved in Antibody Discovery Process, 2021-2035 (USD Billion)
Figure 14.3 Antibody Discovery Services Market for Antigen Designing, 2021-2035 (USD Billion)
Figure 14.4 Antibody Discovery Services Market for Hit Generation, 2021-2035 (USD Billion)
Figure 14.5 Antibody Discovery Services Market for Lead Selection, 2021-2035 (USD Billion)
Figure 14.6 Antibody Discovery Services Market for Lead Optimization, 2021-2035 (USD Billion)
Figure 14.7 Antibody Discovery Services Market for Lead Characterization, 2021-2035 (USD Billion)
Figure 14.8 Global Antibody Discovery Services Market: Distribution by Antibody Discovery Method, 2021-2035 (USD Billion)
Figure 14.9 Antibody Discovery Services Market for Phage Display, 2021-2035 (USD Billion)
Figure 14.10 Antibody Discovery Services Market for Yeast Display, 2021-2035 (USD Billion)
Figure 14.11 Antibody Discovery Services Market for Hybridoma Method, 2021-2035 (USD Billion)
Figure 14.12 Antibody Discovery Services Market for Transgenic Animal based Method, 2021-2035 (USD Billion)
Figure 14.13 Antibody Discovery Services Market for Single Cell based Method, 2021-2035 (USD Billion)
Figure 14.14 Antibody Discovery Services Market for Other Methods, 2021-2035 (USD Billion)
Figure 14.15 Global Antibody Discovery Services Market: Distribution by Nature of Antibody Generated, 2021-2035 (USD Billion)
Figure 14.16 Antibody Discovery Services Market for Humanized Antibodies, 2021-2035 (USD Billion)
Figure 14.17 Antibody Discovery Services Market for Human Antibodies, 2021-2035 (USD Billion)
Figure 14.18 Antibody Discovery Services Market for Chimeric Antibodies, 2021-2035 (USD Billion)
Figure 14.19 Antibody Discovery Services Market for Murine Antibodies, 2021-2035 (USD Billion)
Figure 14.20 Global Antibody Discovery Services Market: Distribution by Region, 2021-2035 (USD Billion)
Figure 14.21 Antibody Discovery Services Market in North America, 2021-2035 (USD Billion)
Figure 14.22 Antibody Discovery Services Market in Europe, 2021-2035 (USD Billion)
Figure 14.23 Antibody Discovery Services Market in Asia-Pacific and Rest of the World, 2021-2035 (USD Billion)
Figure 14.24 Antibody Discovery Services: Market Attractiveness Analysis by Region (USD Billion)
Figure 15.1 Licensing Agreements: Distribution of Financial Components
Figure 15.2 Technology Licensing Deal: Payment Structure
Figure 15.3 Global Antibody Discovery Platforms Market, 2021-2035 (USD Million)
Figure 15.4 Global Antibody Discovery Platforms Market: Distribution by Region, 2021-2035 (USD Million)
Figure 15.5 Antibody Discovery Platforms Market in North America, 2021-2035 (USD Million)
Figure 15.6 Antibody Discovery Platforms Market in Europe, 2021-2035 (USD Million)
Figure 15.7 Antibody Discovery Platforms Market in Asia-Pacific, 2021-2035 (USD Million)
Figure 16.1 Humira®: Annual Sales, 2016-9M 2021 (USD Billion)
Figure 16.2 Keytruda®: Annual Sales, 2016-9M 2021 (USD Billion)
Figure 16.3 Stelara®: Annual Sales, 2016-9M 2021 (USD Billion)
Figure 16.4 Opdivo®: Annual Sales, 2016-9M 2021 (USD Billion)
Figure 16.5 Avastin®: Annual Sales, 2016-9M 2021 (CHF Million)
Figure 17.1 Publication Analysis: Year-wise Distribution of Publications, 2014-2017
Figure 17.2 Publication Analysis: Distribution by Key Journals
Figure 17.3 Publication Analysis: Distribution by Animal Model Used
Figure 17.4 Publication Analysis: Distribution by Antibody Humanization Method Used
Figure 17.6 Antibody Humanization Service and Platform Providers: SWOT Analysis
Figure 17.7 Antibody Humanization Service and Platform Providers: Strengths Overview
Figure 17.8 Antibody Humanization Service and Platform Providers: Weaknesses Overview
Figure 17.9 Antibody Humanization Service and Platform Providers: Opportunities Overview
Figure 17.10 Antibody Humanization Service and Platform Providers: Threats Overview
Figure 18.1 Future Opportunities Related to Upcoming Trends in Drug Discovery
Figure 18.2 Number of Licensing Deals, 2015- 2021

List Of Tables

Table 3.1 Antibody Isotypes: Key Features
Table 3.2 Mechanism of Action of Therapeutic Antibodies against Different Target Classes
Table 3.3 Differences Between Polyclonal and Monoclonal Antibodies
Table 4.1 Antibody Discovery Methods: Advantages and Disadvantages
Table 4.2 List of Approved Monoclonal Antibodies
Table 5.1 List of Antibody Discovery Service Providers
Table 5.2 Antibody Discovery Service Providers: Information on Type of Service(s) Offered
Table 5.3 Antibody Discovery Service Providers: Information on Type of Antibody Discovery Method(s)
Table 5.4 Antibody Discovery Service Providers: Information on Animal Model Used
Table 5.5 Antibody Discovery Service Providers: Information on Type of Antibody Discovered
Table 5.6 Antibody Discovery Service Providers: Information on Purpose of Antibody Discovery
Table 7.1 Antibody Discovery Service Providers: List of Companies Profiled
Table 7.2 Abwiz Bio: Recent Developments and Future Outlook
Table 7.3 Aragen Bioscience: Recent Developments and Future Outlook
Table 7.4 Creative Biolabs: Recent Developments and Future Outlook
Table 7.4 Distributed Bio: Recent Developments and Future Outlook
Table 7.5 ImmunoPrecise Antibodies: Recent Developments and Future Outlook
Table 7.6 Integral Molecular: Recent Developments and Future Outlook
Table 7.7 LakePharma: Recent Developments and Future Outlook
Table 7.8 Abzena: Recent Developments and Future Outlook
Table 7.9 BIOTEM: Recent Developments and Future Outlook
Table 7.10 PX'Therapeutics: Recent Developments and Future Outlook
Table 7.11 ChemPartner: Recent Developments and Future Outlook
Table 7.12 Viva Biotech: Recent Developments and Future Outlook
Table 7.13 WuXi Biologics: Recent Developments and Future Outlook
Table 8.1 List of Antibody Discovery Platform Providers
Table 8.2 Antibody Discovery Platform Providers: Information on Type of Antibody Discovered
Table 8.3 Antibody Discovery: List of Technologies and Platforms
Table 8.4 Antibody Discovery Platforms: Information on Type of Antibody Discovery Method(s)
Table 8.5 Antibody Discovery Platforms: Information on Animal Model Used
Table 8.6 Antibody Discovery Platforms: Information on Patent Availability
Table 10.1 Antibody Discovery Platform Providers: List of Companies Profiled
Table 10.2 Harbour BioMed: Recent Developments and Future Outlook
Table 10.3 ImmunoPrecise Antibodies: Recent Developments and Future Outlook
Table 10.4 Kymab: Recent Developments and Future Outlook
Table 10.5 OmniAb® Technology: Patent Information
Table 10.6 OmniChicken® Technology: Patent Information
Table 10.7 Ligand Pharmaceuticals: Recent Developments and Future Outlook
Table 10.8 MorphoSys: Recent Developments and Future Outlook
Table 11.1 Regional Capability Analysis: Antibody Discovery Platform Providers based in North America
Table 11.2 Regional Capability Analysis: Antibody Discovery Platform Providers based in Europe
Table 11.3 Regional Capability Analysis: Antibody Discovery Platform Providers based in Asia-Pacific
Table 12.1 Antibody Discovery Service and Platform Providers: List of Partnerships and Collaboration, 2015-2021
Table 13.1 Antibody Discovery Service and Platform Providers: List of Funding Instances, 2016-2021
Table 13.2 Funding and Investment Analysis: Summary of Investments
Table 15.1 Developmental / Regulatory Milestones
Table 15.2 Antibody Discovery Platforms: Average Upfront and Average Milestone Payments (USD Million)
Table 16.1 List of Top Ten Selling Therapeutic Antibodies, 2020
Table 17.1 Approved Monoclonal Antibodies: Information on Affinity
Table 17.2 Antibody Humanization and Affinity Maturation: Service and Platform Providers
Table 17.3 Antibody Humanization and Affinity Maturation: Methods Employed by Service and Platform Providers
Table 17.4 Antibody Humanization: List of Recent Publications
Table 17.5 Antibody Humanization: Modified CDR Grafting Methods
Table 18.1 Antibody Discovery Services and Platform Providers: Asia-Pacific Region
Table 19.1 Abveris Antibody: Company Snapshot
Table 19.2 Nidus Biosciences: Company Snapshot
Table 19.3 AvantGen: Company Snapshot
Table 19.4 Single Cell Technology: Company Snapshot
Table 19.5 Distributed Bio: Company Snapshot
Table 19.6 AbCellera: Company Snapshot
Table 19.7 AbGenics Life Sciences: Company Snapshot
Table 19.8 CDI Laboratories: Company Snapshot
Table 19.9 AP Biosciences: Company Snapshot
Table 19.10 YUMAB: Company Snapshot
Table 19.12 Antibody Solutions: Company Snapshot
Table 19.13 Ligand Pharmaceuticals: Company Snapshot
Table 19.14 LakePharma: Company Snapshot
Table 21.1 Antibody Discovery Service Providers: Distribution by Year of Establishment
Table 21.2 Antibody Discovery Service Providers: Distribution by Company Size
Table 21.3 Antibody Discovery Service Providers: Distribution by Location of Headquarters
Table 21.4 Antibody Discovery Service Providers: Distribution by Type of Service Offered
Table 21.5 Antibody Discovery Service Providers: Distribution by Type of Antibody Discovery Method
Table 21.6 Antibody Discovery Service Providers: Distribution by Animal Model Used
Table 21.7 Antibody Discovery Service Providers: Distribution by Type of Antibody Discovered
Table 21.8 Antibody Discovery Service Providers: Distribution by Purpose of Antibody Discovery
Table 21.9 Abzena: Annual Revenues, 2014-2018 (GBP Million)
Table 21.10 ImmunoPrecise Antibodies: Annual Revenues, 2016-2021 (USD Million)
Table 21.11 Viva Biotech: Annual Revenues, 2016-H1 2021 (RMB Million)
Table 21.12 WuXi Biologics: Annual Revenues, 2015-H1 2021 (RMB Billion)
Table 21.13 Antibody Discovery Platform Providers: Distribution by Year of Establishment
Table 21.14 Antibody Discovery Platform Providers: Distribution by Company Size
Table 21.15 Antibody Discovery Platform Providers: Distribution by Location of Headquarters
Table 21.16 Antibody Discovery Platform Providers: Distribution by Type of Antibody Discovered
Table 21.17 Antibody Discovery Platforms: Distribution by Type of Antibody Discovery Method
Table 21.18 Antibody Discovery Platforms: Distribution by Animal Model Used
Table 21.19 Antibody Discovery Platforms: Distribution by Patent Availability
Table 21.20 ImmunoPrecise Antibodies: Annual Revenues, 2016-2021 (USD Million)
Table 21.21 Ligand Pharmaceuticals: Annual Revenues, 2014-9M 2021 (USD Million)
Table 21.22 MorphoSys: Annual Revenues, 2014-9M 2021 (USD Million)
Table 21.23 Partnerships and Collaborations: Cumulative Trend by Year, 2015-2021
Table 21.24 Partnerships and Collaborations: Distribution by Type of Partnership
Table 21.25 Partnerships and Collaborations: Distribution by Year and Type of Partnership, 2015-2020
Table 21.26 Partnerships and Collaborations: Distribution by Type of Company (Service / Platform Providers)
Table 21.27 Partnerships and Collaborations: Distribution by Type of Antibody Discovered
Table 21.28 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Table 21.29 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Table 21.30 Most Active Players: Distribution by Number of Partnerships
Table 21.31 Most Popular Technologies: Distribution by Number of Partnerships
Table 21.32 Partnerships and Collaborations: Regional Distribution
Table 21.33 Funding and Investment Analysis: Distribution by Type of Funding and Year of Establishment
Table 21.34 Funding and Investment Analysis: Cumulative Year-wise Distribution of Funding Instances, 2016-2021
Table 21.35 Funding and Investment Analysis: Year-wise Distribution of Funding Instances by Type of Company, (2016-2021)
Table 21.36 Funding and Investment Analysis: Distribution by Cumulative Amount Invested, 2016-2021 (USD Million)
Table 21.37 Funding and Investment Analysis: Year-wise Distribution of Funding Instances by Amount Invested, 2016-2021 (USD Million)
Table 21.38 Funding and Investment Analysis: Year-wise Distribution of the Amount Raised by Type of Company, 2016-2021 (USD Million)
Table 21.39 Funding and Investment Analysis: Distribution of Instances by Type of Funding,
Table 21.40 Funding and Investment Analysis: Distribution of Type of Funding and Amount Invested, (USD Million)
Table 21.41 Most Active Player: Distribution by Number of Funding Instances
Table 21.42 Most Active Player: Distribution by Total Amount Invested (USD Million)
Table 21.43 Most Active Investors: Distribution by Number of Funding Instances
Table 21.44 Funding and Investment Analysis: Distribution by Geography
Table 21.45 Funding and Investment Analysis: Regional Distribution of Funding Instances
Table 21.46 Global Antibody Discovery Services Market, 2021-2035 (USD Billion): Base, Conservative and Optimistic Scenarios
Table 21.47 Global Antibody Discovery Services Market: Distribution by Steps Involved in Antibody Discovery Process, 2021-2035: Base, Conservative and Optimistic Scenarios
Table 21.48 Antibody Discovery Services Market for Antigen Designing, 2021-2035
Table 21.49 Antibody Discovery Services Market for Hit Generation, 2021-2035
Table 21.50 Antibody Discovery Services Market for Lead Selection, 2021-2035
Table 21.51 Antibody Discovery Services Market for Lead Optimization, 2021-2035
Table 21.52 Antibody Discovery Services Market for Lead Characterization, 2021-2035
Table 21.53 Global Antibody Discovery Services Market: Distribution by Antibody Discovery Method, 2021-2035: Base, Conservative and Optimistic Scenarios
Table 21.54 Antibody Discovery Services Market for Phage Display, 2021-2035
Table 21.55 Antibody Discovery Services Market for Yeast Display, 2021-2035
Table 21.56 Antibody Discovery Services Market for Hybridoma Method, 2021-2035
Table 21.57 Antibody Discovery Services Market for Transgenic Animal Based Method, 2021-2035
Table 21.58 Antibody Discovery Services Market for Single Cell Based Method, 2021-2035
Table 21.59 Antibody Discovery Services Market for Other Methods, 2021-2035
Table 21.60 Global Antibody Discovery Services Market: Distribution by Nature of Antibody Generated, 2021-2035: Base, Conservative and Optimistic Scenarios
Table 21.61 Antibody Discovery Services Market for Humanized Antibodies, 2021-2035
Table 21.62 Antibody Discovery Services Market for Human Antibodies, 2021-2035
Table 21.63 Antibody Discovery Services Market for Chimeric Antibodies, 2021-2035
Table 21.64 Antibody Discovery Services Market for Murine Antibodies, 2021-2035

Table 21.65 Global Antibody Discovery Services Market: Distribution by Region, 2021-2035: Base, Conservative and Optimistic Scenarios
Table 21.66 Antibody Discovery Services Market in North America, 2021-2035
Table 21.67 Antibody Discovery Services Market in Europe, 2021-2035
Table 21.68 Antibody Discovery Services Market in Asia-Pacific and Rest of the World, 2021-2035
Table 21.69 Global Antibody Discovery Platforms Market, 2021-2035 (USD Million): Base, Conservative and Optimistic Scenarios
Table 21.70 Global Antibody Discovery Platforms Market: Distribution by Region, 2021-2035 (USD Million): Base, Conservative and Optimistic Scenarios
Table 21.71 Antibody Discovery Platforms Market in North America, 2021-2035
Table 21.72 Antibody Discovery Platforms Market in Europe, 2021-2035
Table 21.73 Antibody Discovery Platforms Market in Asia-Pacific, 2021-2035
Table 21.74 Humira®: Annual Sales, 2016-9M 2021 (USD Billion)
Table 21.75 Keytruda®: Annual Sales, 2016-9M 2021 (USD Billion)
Table 21.76 Stelara®: Annual Sales, 2016-9M 2021 (USD Billion)
Table 21.77 Opdivo®: Annual Sales, 2016-9M 2021 (USD Billion)
Table 21.78 Avastin®: Annual Sales, 2016-9M 2021 (CHF Million)
Table 21.79 Number of Licensing Deals, 2015- 2021

List Of Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

1. 2BScientific
2. 3D Medicines 
3. 3E Bioventures Capital
4. 3SBio
5. A*STAR's Genome Institute of Singapore
6. AAT Bioquest 
7. Ab Initio Biotherapeutics
8. Ab Studio
9. ABBA Therapeutics
10. AbBioSci
11. Abbiotec
12. AbbVie
13. Abcam
14. AbCellera
15. Abcentra
16. Abcepta
17. AbCheck
18. ABclonal 
19. Abcore 
20. ABDYS
21. Abeome
22. Abexxa Biologics 
23. ABGENEX
24. AbGenics Life Sciences
25. Abilita Bio
26. ABL Bio
27. Ablexis
28. Abnova
29. Abpro
30. AbSano
31. Absea  
32. Absolute Antibody
33. Abveris 
34. AbVision
35. Abwiz Bio
36. Abzena
37. Abzyme Therapeutics
38. AC Immune
39. Accel
40. Acceleron Pharma
41. Accurus Biosciences
42. Achaogen
43. ACYTE Biotech
44. Adagene
45. Adaptate Biotherapeutics
46. Adimab
47. Adipogen Life Sciences 
48. Aduro Biotech
49. Advantech
50. Advantech Capital
51. AffinityImmuno
52. Affitech
53. Agency for Science, Technology and Research
54. Agenus
55. Agro-Bio 
56. AIMM Therapeutics
57. Aimmune Therapeutics
58. Aisling Capital
59. Akeagen 
60. Akeso Biopharma
61. Aldevron
62. Alector
63. Alligator Bioscience
64. Allogene Therapeutics
65. Alloy Therapeutics
66. Ally Bridge 
67. AlpaLife 
68. Alta Partners
69. Alvaxa Biosciences (Acquired by Sensei Biotherapeutics)
70. ALX Oncology 
71. alytas therapeutics 
72. Alzheimer's Drug Discovery Foundation
73. Amgen
74. Amgen Ventures
75. Ampersand Capital Partners
76. AMSBIO
77. AnaImmune
78. Analytics Engine
79. AnaptysBio
80. Andera Partners
81. Angel BioScience
82. Antagene
83. Antibody Design Labs
84. Antibody Solutions
85. Antiverse
86. AP Biosciences
87. Apexigen
88. APITBIO 
89. Applied Biological Materials(abm)
90. AprilBio
91. Aptevo Therapeutics
92. Aquila BioMedical
93. Aquila Capital
94. Aquilo Capital Management
95. Aragen Bioscience
96. ARCH Venture Partners
97. Arcus Biosciences
98. argenx
99. Aridis Pharmaceuticals
100. Aro Biotherapeutics
101. Aronora
102. Arsanis
103. ArtiaBio 
104. Artizan Biosciences
105. ARVYS Proteins 
106. Assistant Secretary for Preparedness and Response
107. Astellas Pharma
108. AstraZeneca
109. aTen Therapeutics
110. Atreca
111. ATUM
112. Autolus Therapeutics
113. AvantGen
114. AVIC Capital
115. Aviva Systems Biology 
116. AxioMx
117. Ballast Point Ventures
118. Bayer
119. BBI Group
120. BeiGene
121. Beijing Shijilongxin Investment
122. BenchSci 
123. Berkeley Lights
124. Betta Pharmaceuticals
125. BRL
126. Bharat Innovation Fund
127. Bhat Bio-tech
128. Bill & Melinda Gates Foundation
129. Bio- Rad Laboratories
130. BioAtla
131. BioConnect
132. Biocure Technology 
133. Biocytogen
134. BioDiscovery
135. BioDuro
136. Biogen
137. Biointron
138. BioInvent
139. BiologicsCorp(BIC)
140. Biomatics Capital
141. Biomolecular Discovery Services
142. BioNTech
143. Bio-Rad Laboratories
144. BioSavita
145. Biosion
146. Biotechnology Value Fund
147. Biotecnol
148. BIOTEM
149. Biotheus
150. Bioz 
151. Birchmere Labs
152. Bird Rock Bio
153. Blue Sky BioServices
154. bluebird bio
155. Boehringer Ingelheim
156. Boster Bio
157. Boston Children's Hospital
158. Boxer Capital
159. Brain Canada
160. Bristol-Myers Squibb
161. Broteio Pharma
162. Burrage Capital
163. CALIXAR
164. CANbridge
165. Cancer Prevention and Research Institute of Texas
166. Capra Science 
167. Capralogics 
168. Carterra
169. Catalent Biologics
170. CBC Group
171. CCB Capital
172. CDH Investments
173. CDI Laboratories
174. Celexion
175. Celgene
176. Cell Signaling Technology
177. Cellaria
178. Celsius Therapeutics
179. Centers for Disease Control and Prevention (CDC)
180. Charles River Laboratories
181. ChemBio Discovery Solutions
182. Chemical Abstracts Service (CAS)
183. ChemPartner
184. Chia Tai Tianqing Pharmaceutical 
185. China Life Investment Holding
186. China Life Private Equity Investment
187. ChinaEquity Group (CEG)
188. Chiome Bioscience
189. Chugai Pharmabody Research
190. Chugai Pharmaceutical
191. Cilag
192. Citryll
193. City of Hope
194. Columbia University Irving Medical Center
195. Compass Therapeutics
196. Cormorant Asset Management
197. Corvidia Therapeutics
198. Cosmo Bio
199. Cowen Healthcare Investments
200. Cowin Venture Capital
201. CR-CP Life Science Fund
202. Creative Biolabs
203. Creative Biostructure
204. Creative Diagnostics
205. Crescendo Biologics
206. Crystal Bioscience
207. CSL Behring
208. CStone Pharmaceuticals
209. CureVac
210. CUSABIO
211. Cyclogenix 
212. Cygnus Technologies 
213. DAFNA Capital Management
214. Daiichi Sankyo
215. Dako
216. Dana-Farber Cancer Institute
217. DaTaMabs
218. DBA ITALIA
219. DCVC (Data Collective) 
220. Decheng Capital
221. Defense Advanced Research Projects Agency (DARPA)
222. Delian Capital
223. Denali Therapeutics
224. Detaibio Tech 
225. Diagnostic BioSystems 
226. Dianomi Therapeutics
227. Diatheva
228. Digital Proteomics
229. Distributed Bio
230. DJS Antibodies
231. Dotmatics
232. Dualogics 
233. Early Drug Development Group (E2DG)
234. EcoR1 Capital
235. Efung Capital
236. Eight Roads
237. Eisai
238. Elabscience 
239. Eli Lilly and Company
240. Elpis Biopharmaceuticals
241. Emergent BioSolutions
242. E-nnovation Life Sciences
243. Enterprise Singapore
244. Enthera
245. Entos Pharmaceuticals
246. Envigo
247. EpimAb Biotherapeutics
248. Epiphron Capital Group
249. EUPROTEIN
250. Eureka Therapeutics
251. European Investment Bank
252. European Molecular Biology Laboratory (EMBL)
253. Eurostars
254. Evotec
255. Exelixis
256. Exiris
257. exonbio
258. FairJourney Biologics
259. Faron Pharmaceuticals
260. FCMI Parent
261. Ferring Pharmaceuticals
262. Five Prime Therapeutics
263. Flagship Pioneering
264. Flanders Innovation and Entrepreneurship
265. Floodgate
266. ForteBio
267. Fortune Capital Services
268. Forty Seven
269. F-Prime Capital
270. Fred Hutchinson Cancer Research Center
271. FREJOY Investment Management
272. Fusion Antibodies
273. Fusion Pharmaceuticals
274. G&P Biosciences
275. G.N. Tech Venture
276. Genagon Therapeutics
277. Gene Techno Science
278. GeneBeyond
279. Genedata Biologics
280. GeneFrontier
281. Geneious Biologics
282. General Atlantic
283. GENEWIZ 
284. Genmab
285. Genor Biopharma
286. GenoSafe 
287. Genosco
288. GenScript
289. GenWay Biotech 
290. GHO Capital
291. GIC
292. GigaGen
293. Gilead Sciences
294. GSK
295. Glenmark Pharmaceuticals
296. Glythera
297. Gopher Asset Management
298. GP Healthcare Capital
299. Green Mountain Antibodies 
300. Grenoble Alpes University Hospital
301. Grifols
302. Gustave Roussy
303. GV20 Oncotherapy
304. H3 Biomedicine
305. Harbour BioMed
306. Harpoon Therapeutics
307. HD Biosciences
308. Helix BioPharma
309. Henlix Biotech
310. Heptares Therapeutics
311. Hercules Capital
312. Heritas Capital Management
313. HiFiBiO Therapeutics
314. Hillhouse Capital 
315. HJB
316. Hony Capital
317. HOPU Investments
318. Horizon Discovery 
319. Huaxing Growth Capital
320. Hummingbird Bioscience
321. i2 Pharmaceuticals
322. Ibex Biosciences
323. Icosagen
324. IDG Capital
325. IFB Hamburg
326. IGEM Therapeutics
327. I-Mab Biopharma
328. iMetabolic Biopharma
329. Immatics Biotechnologies
330. Immune Biosolutions
331. Immune Pharmaceuticals
332. ImmunoChina Pharmaceuticals
333. ImmunoGenes
334. Immunome
335. Immunomic Therapeutics
336. ImmunoPrecise Antibodies
337. ImmunoQure
338. In-Cell-Art
339. Incyte
340. Indivumed
341. Inhibrx
342. Innate Pharma
343. Innogene Kalbiotech
344. Innovagen  
345. Innovate UK
346. Innovative Targeting Solutions
347. Innovent Biologics
348. Inotiv 
349. Institut National de la Santé et de la Recherche Médicale (INSERM)
350. Institute for Research in Biomedicine
351. Intarcia Therapeutics
352. Integral Molecular
353. IntelliCyt
354. International Livestock Research Institute (ILRI) 
355. Invenra
356. Invest Northern Ireland
357. Invetx 
358. IONTAS
359. IP  
360. IRBM
361. Isogenica
362. Italian National Institute of Health
363. ITBMed
364. iTeos Therapeutics
365. Janssen Biotech
366. Janssen Pharmaceutical
367. JDRF T1D Fund
368. Jiangsu Hengrui Medicine
369. Johnson & Johnson Innovation
370. Jounce Therapeutics
371. Juno Therapeutics
372. Just Biotherapeutics (Acquired by Evotec)
373. JW Bioscience
374. Kadmon
375. Kairos Therapeutics 
376. Kaken Pharmaceutical
377. Karolinska Institutet
378. Kemp Proteins (formerly known as Kempbio)
379. Keystone Capital Partners
380. Kite Pharma
381. KMD 
382. Kodiak Sciences
383. Kymab
384. LabCorp
385. Labtoo
386. LakePharma
387. LAMPIRE Biological Laboratories
388. Lanier Biotherapeutics
389. Lava Therapeutics
390. Leadgene Biomedical
391. Leading Biology
392. Legend Capital
393. Legend Star
394. Leidos Biomedical Research
395. LEO Pharma
396. LG Chem
397. Life Science Partners
398. LifeArc
399. LifeTein
400. Ligand Pharmaceuticals
401. Light Chain Bioscience
402. Lilly Ventures
403. Lineage Biosciences (Acquired by AbCellera)
404. Linear Venture
405. Lipum
406. Lonza
407. Lundbeck
408. Luye Pharma  
409. LYFE Capital
410. MAB Discovery
411. MabGenesis
412. Mablytics
413. Mabpharm
414. MAbSilico 
415. MabSpace Biosciences
416. Mabtech
417. MabVax Therapeutics
418. MacroGenics
419. Magenta Therapeutics
420. Maine Biotechnology Services
421. Malin
422. Maravai LifeSciences 
423. Massachusetts General Hospital
424. MassBiologics
425. Maverick Therapeutics
426. MD Anderson Cancer Center
427. MedAbome
428. Medicilon
429. MedImmune
430. Medix Biochemica 
431. MEMO Therapeutics
432. Memorial Sloan Kettering Cancer Center
433. Merck
434. Merus
435. MI-mAbs 
436. Mirae Asset Financial 
437. Mitsubishi Tanabe Pharma
438. Mitsubishi UFJ Capital
439. ModiQuest Research
440. Molcure
441. Molecular Devices
442. Molecular Templates
443. MolMed
444. Moradec
445. MorphoSys
446. Mount Sinai Health System
447. MPM Capital
448. MRL Ventures Fund
449. MSM Protein Technologies
450. Mycenax Biotech
451. Myrio Therapeutics (Myrio)
452. NanoString Technologies
453. Nara Medical University 
454. National Cancer Institute
455. National Center for Research and Development
456. National Centre for Biomolecular Research
457. National Heart, Lung and Blood Institute
458. National Institute of Allergy and Infectious Diseases
459. National Institute of General Medical Sciences
460. National Institutes of Health
461. NB Health Laboratory
462. NBE-Therapeutics
463. NeoBiotechnologies
464. NeoClone
465. Neon Therapeutics
466. neoX Biotech
467. Nest.Bio Ventures
468. Neurimmune
469. New World TMT
470. Nidus BioSciences
471. NJCTTQ
472. Nkarta Therapeutics
473. North Coast Biologics
474. NovaRock Biotherapeutics
475. Novartis
476. Novo Nordisk
477. Numab Therapeutics
478. NYU Langone Health
479. Oak Biosciences 
480. Oblique Therapeutics
481. Oceanpine Capital
482. Olympic Protein Technologies
483. Oncothyreon
484. Ono Pharmaceutical
485. Open Monoclonal Technology
486. OrbiMed Advisors
487. OREGA Biotech
488. ORI Healthcare Fund
489. OriGene Technologies
490. OriMAbs
491. OSE Immunotherapeutics 
492. Ossianix
493. Oxford Sciences Innovation
494. Paladin Capital
495. Pandion Therapeutics 
496. Panoply Bio
497. Pascal Biosciences 
498. Pediatric Brain Tumor Consortium
499. Penn Medicine
500. Pennsylvania Industrial Development Authority
501. Perseus Proteomics
502. Pfizer
503. pH Pharma
504. Phanes Therapeutics
505. PharmAbcine
506. PharmaLegacy
507. Pierre Fabre
508. Polaris Partners
509. Potenza Therapeutics
510. PPF 
511. Precision Antibody
512. ProMab Biotechnologies
513. Protein Alternatives (PROALT)
514. ProteoGenix
515. ProtTech
516. Proxima Ventures
517. Purdue Pharma
518. Pure Biologics
519. PX'Therapeutics
520. Qianhai Qinzhi Capital
521. Qiming Venture Partners
522. QIMR Berghofer Medical Research Institute
523. QoolAbs
524. Quan Funds
525. Quebec Consortium for Drug Discovery (CQDM)
526. Queen's University
527. Rapid Novor
528. RayBiotech
529. RD-Biotech
530. Redalpine Venture Partners
531. Redmile 
532. Regeneron Pharmaceuticals
533. Regione Lazio
534. Resonant Therapeutics
535. Retrogenix
536. RevMab Biosciences 
537. Revolve Biotechnologies
538. Rezolute
539. Rhenman & Partners Asset Management
540. Roche
541. Rockland Immunochemicals
542. RubrYc Therapeutics
543. Rx Biosciences
544. SAB Biotherapeutics
545. Sahlgrenska University Hospital
546. Samsara BioCapital
547. Samsara Networks
548. San Diego Biomedical Research Institute
549. Sanofi
550. Sanyou Biopharmaceuticals
551. SARomics Biostructures
552. Sartorius 
553. SBH Sciences 
554. Schroder Adveq
555. Science Exchange 
556. Scotia Biologics
557. Sea Lane Biotechnologies
558. Seeds Capital
559. Selecxine
560. Sensei Biotherapeutics
561. Sequoia Capital China
562. Serum Institute of India
563. Sevion Therapeutics
564. Shandong Boan Biotechnology 
565. Shanghai Junshi Biosciences
566. Shenyang Sunshine Pharmaceuticals
567. Shenzhen GTJA Investment Group
568. Shenzhen Hepalink Pharmaceutical
569. Shenzhen Innovation Capital Investment
570. Shilps Sciences
571. Shire
572. Sichenzia Ross Ference
573. Sichuan Kelun-Biotech Biopharmaceutical
574. Siegfried Holding
575. Silverton Partners
576. Simcere Pharmaceutical
577. Simon Fraser University
578. Single Cell Technology
579. Sino Biological
580. Sinobioway
581. Six.02 Bioservices 
582. SK Holdings
583. Sofinnova Partners
584. Sorrento Therapeutics
585. SOTIO
586. South Dakota Equity Partners
587. SouthernBiotech
588. Specifica
589. Sphere Fluidics
590. Standford University
591. State Development & Investment
592. State of Wisconsin Investment Board (SWIB)
593. Straterx
594. Summit Partners
595. Surface Oncology
596. Surveyor Capital
597. Sutro Biopharma
598. Suzhou Bright Scistar Biotechnology (BSBIO)
599. Suzhou Oriza Holdings
600. Syd Labs
601. Symphogen
602. Synbio Technologies
603. Syngene
604. Synthelis
605. TA Associates
606. Takeda
607. Talem Therapeutics
608. Tanabe Research Laboratories
609. Tasgen Bio-Tech
610. Tasly Biopharmaceuticals
611. TC BioPharm 
612. Technical University of Denmark
613. Telix Pharmaceuticals
614. Temasek Holdings
615. TeneoBio
616. TESARO
617. TetraGenetics
618. Teva Pharmaceutical Industries
619. TG Therapeutics
620. The Antibody Company
621. The University of Texas MD Anderson Cancer Center
622. The University of Tokyo
623. The Wistar Institute
624. Theraclone Sciences
625. Theranyx
626. Thermo Fisher Scientific
627. Thiel Capital
628. Third Point Ventures
629. Third Venture Biopharma
630. ThromboGenics
631. Tizona Therapeutics
632. Tmunity Therapeutics
633. Torch Biosciences
634. TRACON Pharmaceuticals
635. Transcenta Holding
636. Transgene
637. TRIANNI
638. Tri-Institutional Therapeutics Discovery Institute
639. Tsinghua University
640. Twist Biopharma
641. Twist Bioscience
642. UK Innovation & Science Seed Fund
643. University College London
644. University of Navarra
645. University of Oxford
646. University of Southampton
647. University of Surrey
648. University of Technology Sydney
649. University of Texas
650. U-Protein Express
651. US Department of Defense
652. Vaccinex
653. Vall d'Hebron Institute of Oncology
654. Valneva
655. Velabs Therapeutics
656. venBio
657. VERAXA Biotech
658. Vertex Holdings 
659. VI Ventures
660. Vinnova
661. Vir Biotechnology
662. Visterra
663. Vital Venture Capital
664. Viva Biotech
665. Voyager Therapeutics
666. Washington University School of Medicine
667. Watson Investments
668. Wellington Management
669. Wisconsin Alumni Research Foundation
670. Woodford Investment Management
671. Woodford Patient Capital Trust
672. WuXi AppTec
673. Wuxi Biologics
674. XBiotech
675. xCella Biosciences
676. X-Chem
677. Xencor
678. XOMA
679. Y- Biologics 
680. Yale Cancer Center
681. Yinuoke
682. YUMAB
683. Yurogen Biosystems
684. Zai Lab
685. Zebra Biologics
686. Zhejiang Teruisi Pharmaceutical
687. Zheshang Venture Capital
688. ZoonBio Biotechnology 
689. Zumutor Biologics
690. Zurich Cantonal Bank
691. Zydus Cadila
692. Zymeworks